Clinical trials: Cystic Fibrosis Pulmonary Exacerbation
Cystic Fibrosis in Children, Exercise Capacity
Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
The aim of this study to investigate and compare functional capacity with different tests and to evaluate the relationship between functional capacity and quality of life during acute pulmonary exacerbation in children with…
- Trial name
- NCT04174664
- Testing
- 1-minute sit to stand test
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
Cystic Fibrosis, Cystic Fibrosis in Children
Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis
The objective of this study was to evaluate the effect of a physical exercise program on the functional capacity of children and adolescents with cystic fibrosis hospitalized at the Hospital de Clínicas of Porto Alegre (HCPA)…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis in Children, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis With Exacerbation
- Trial name
- NCT03273959
- Testing
- Exercise protocol
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cystic Fibrosis
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older.
- Trial name
- NCT03451045
- Testing
- Lenabasum 20 mg, Lenabasum 5 mg
- Where
- 105 sites in United States, Austria and 19 more
- Volunteers
- 447 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Cystic Fibrosis
A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
Cystic fibrosis (CF) is an inherited disorder which results in increased thickness of secretions, especially in the lungs. By adulthood, the majority of patients with CF will have a bacteria living in their lungs, called…
- Trial name
- CISTIC (NCT01667094)
- Testing
- Intermittent, short infusion Ceftazidime, Continuous infusion Ceftazidime, Intermittent, short infusion Meropenem
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- The Alfred
Cystic Fibrosis
19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation
The purpose of this study is to use perfluorinated gas imaging to highlight regions of functional variation within the lungs of participants with cystic fibrosis (CF), and to correlate this with changes in spirometry, lung…
- Trial name
- NCT03497117
- Testing
- Lung Clearance Index, MRI with PFP
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective
Given the treatment burden and excess morbidity and mortality associated with acute infective exacerbations in cystic fibrosis, a clear understanding of the mechanisms involved in the origins of an infective exacerbation and the…
- Trial name
- NCT01306279
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Cystic Fibrosis, Lung Inflammation
TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era
Progressive destruction of the lungs is the main cause of shortened life expectancy in people with cystic fibrosis (pwCF). Inflammation and respiratory infections play a key role in CF lung disease.
- Conditions
- Cystic Fibrosis, Lung Inflammation, Lung Infection, Lung Disease; Cystic
- Trial name
- TERRIFIC-MILE (NCT05752019)
- Where
- Netherlands
- Volunteers
- 103 people
- Sponsor
- Erasmus Medical Center
Cystic Fibrosis
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
This study will be performed at the University of Washington. Forty subjects with Cystic Fibrosis will be enrolled, with 20 randomized into the usual care arm and 20 randomized into the intervention arm.
- Trial name
- NCT00850551
- Testing
- Early Intervention
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
Cystic Fibrosis
e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population
The goal of this clinical trial is to analyse the impact of a telematic assessment and monitoring protocol in people with cystic fibrosis, in order to identify exacerbations early, thus preventing loss of lung function and…
- Trial name
- NCT06313827
- Testing
- Exercise plus Monitoring Group (TG-2), Exercise plus monitoring and follow-up group (TGF-3), Exercise Group (CG-1)
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- University of Valencia
Non Cystic Fibrosis Bronchiectasis
Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.
The primary objective of the trial was to investigate the effect of the use of inhaled colistimethate sodium (CMS), administered twice a day (b.i.d.) via a specific nebulizer for 12 months, compared to placebo in subjects with…
- Trial name
- PROMIS-II (NCT03460704)
- Testing
- CMS
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 287 people
- Sponsor
- Zambon SpA
Cystic Fibrosis, Pulmonary Exacerbation
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
Presently, effectiveness of treatments for CF lung disease is judged by improvement in lung function (FEV1). However, in CF patients, FEV1 can range from severely decreased to normal, and improvements may occur slowly.
- Trial name
- NCT00727285
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
Probiotics in Cystic Fibrosis
Cystic fibrosis (CF) is a complex systemic disease that mainly involves the respiratory and gastrointestinal (GI) tracts. The polymicrobial community composition of respiratory and GI tracts is influenced by both genetic and…
- Trial name
- NCT01956916
- Testing
- Lactobacillus rhamnosus GG
- Where
- 5 sites in Italy
- Volunteers
- 110 people
- Sponsor
- Federico II University
Cystic Fibrosis
Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations
The investigators aim to assess whether pulmonary MRI (hyperpolarised 129Xe ventilation imaging [Xe-MRI]) can detect changes in ventilation defects in patients with CF before and after treatment for a pulmonary exacerbation.
- Trial name
- NCT02606487
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
Muco Smartphone Exacerbation
Exacerbation in cystic fibrosis play an important role in terms of mortality and morbidity. Exacerbation frequencies is relatedto FEV1 decline and mortality.
- Trial name
- MUSE (NCT02122289)
- Testing
- Application of Smartphone, No application Smartphone
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients
YKL-40 is proposed as a biomarker of various inflammatory disease diabetes and lung disease including cystic fibrosis. In those cross-sectional studies, a unique value of YKL-40 is used to correlate with clinical, physiological…
- Trial name
- Kin_YKL_CF (NCT02305784)
- Where
- Canada
- Volunteers
- 188 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Cystic Fibrosis
Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF
The aim of this study is to develop a reliable and valid instrument to measure symptom management (experience and / or management strategies) during exacerbation episodes in CF patients.
- Trial name
- NCT02464267
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University of Zurich
Cystic Fibrosis
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study
STOP PEDS is a pilot study of children with CF ages 6-18 across 10 sites in North America. The primary goal is to assess the acceptability and feasibility of a multicenter randomized trial comparing immediate antibiotics versus…
- Trial name
- STOP-PEDS (NCT04608019)
- Testing
- Immediate Antibiotics, Tailored Treatment
- Where
- 10 sites in United States
- Volunteers
- 121 people
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
Cystic Fibrosis
Home Monitoring to Predict Exacerbation in Cystic Fibrosis
The study aims to establish if it is possible for people with Cystic Fibrosis to monitor a number of parameters on a daily basis at home which might predict respiratory infections before they have symptoms and which might also…
- Trial name
- SmartCare (NCT02416375)
- Where
- 2 sites in United Kingdom
- Volunteers
- 147 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis
High Frequency Chest Wall Oscillation and Cystic Fibrosis
High frequency chest wall oscillation (HFCWO) has been shown to increase tracheal mucus clearance compared with a control group.
- Trial name
- NCT01057524
- Testing
- High Frequency Chest Wall Oscillation (HFCWO), Usual airway clearance
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- Imperial College London